Akari Therapeutics (AKTX) AI Stock Analysis

• Market Cap: $10.92M
• Dividend Yield: N/A
• Average Volume (3M): 29.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 24,758,558
• 10 Day Avg. Volume: 25,490
• 30 Day Avg. Volume: 29,838
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score reflects significant financial instability and mixed technical indicators. Positive corporate events, such as the merger and strategic advancements, provide potential upside, but the company's precarious financial condition poses substantial risks.

Akari Therapeutics Business Overview & Revenue Model

Company Description

Akari Therapeutics (AKTX) is a biopharmaceutical company focused on developing treatments for rare and orphan diseases, particularly those involving the complement and leukotriene systems. The company's lead product candidate, nomacopan, is a bifunctional inhibitor that targets both complement C5 and leukotriene B4, positioning it for potential use in a variety of inflammatory and autoimmune conditions.

How the Company Makes Money

Akari Therapeutics makes money primarily through the development and potential commercialization of its lead product candidate, nomacopan. The company's revenue model is typical of a biotech firm in the clinical development stage, relying heavily on research and development milestones, grants, and possible future licensing agreements or partnerships with larger pharmaceutical companies. As nomacopan progresses through clinical trials, Akari may enter into strategic collaborations or licensing agreements, which could provide upfront payments, milestone payments, and royalties on future sales if the product is successfully brought to market.

Akari Therapeutics Financial Statement Overview

Summary

Akari Therapeutics is experiencing significant financial instability, with consistent losses, negative equity, and reliance on external financing. These challenges are typical for early-stage biotech firms but pose high risks for investors.

Income Statement

Akari Therapeutics shows a consistent lack of revenue generation over the years, which is typical for early-stage biotechnology companies focusing on R&D. The company has faced increasing net losses, with the most recent TTM losses larger than previous annual figures. This indicates significant challenges in controlling operational costs, impacting margins negatively.

Balance Sheet

The balance sheet reveals a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The company has introduced debt, increasing financial risk, especially with negative equity, suggesting potential solvency issues. The declining equity ratio and increasing liabilities highlight financial instability.

Cash Flow

The cash flow statement indicates persistent negative operating cash flow, pointing to operational challenges in generating cash. The company relies heavily on financing activities to fund its operations, as free cash flow remains negative. The lack of revenue generation further compounds the weak cash flow situation.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-13.00K	―	―	―	―	-19.20K
	EBIT
-20.16M	-16.81M	-23.09M	-17.21M	-17.98M	-24.87M
	EBITDA
-20.11M	-16.80M	-23.08M	-17.21M	-20.44M	-24.73M
	Net Income Common Stockholders
-19.52M	-10.01M	-6.97M	-17.61M	-17.60M	-21.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.97M	3.85M	13.25M	9.36M	14.06M	5.73M
	Total Assets
16.45M	4.36M	13.83M	11.65M	17.59M	10.31M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-5.97M	-3.85M	-13.25M	-9.36M	-14.06M	-5.73M
	Total Liabilities
3.08M	4.58M	12.04M	6.09M	5.22M	6.47M
	Stockholders Equity
13.38M	-229.00K	1.79M	5.55M	12.38M	3.84M
Cash Flow		Free Cash Flow
-10.43M	-16.43M	-21.50M	-18.85M	-16.95M	-12.26M
	Operating Cash Flow
-10.43M	-16.43M	-21.50M	-18.85M	-16.95M	-12.26M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
8.83M	7.02M	25.29M	14.29M	25.07M	11.99M

Akari Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.12, and below the 200-day MA of 2.30, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 39.64 is Neutral, neither overbought nor oversold. The STOCH value of 25.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.

Akari Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	58 Neutral	$5.90B	268.98	12.21%	―	40.80%	100.62%
IFRX	52 Neutral	$79.22M	―	-62.38%	―	178.84%	-40.60%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
AKTX	44 Neutral	$10.92M	―	291.66%	―	―	―
INBX	42 Neutral	$196.87M	―	919.96%	―	―	―
ANVS	38 Underperform	$31.18M	―	-596.70%	―	―	9.74%
ALVR	37 Underperform	$29.22M	―	-45.37%	―	―	72.12%

Akari Therapeutics Corporate Events

Akari Therapeutics Showcases Advancements in Cancer Treatment

Akari Therapeutics announced an updated corporate presentation that highlights their advancements in bi-functional ADCs for cancer treatment. The company is leveraging its novel discovery engine to develop innovative products like AKTX-101, with promising preclinical results and potential strategic partnerships, which could significantly enhance its market position and stakeholder value.

Akari Therapeutics Announces New CEO and Director Changes

Akari Therapeutics has appointed Dr. Samir R. Patel as the permanent Chief Executive Officer, effective December 16, 2024, following his tenure as interim CEO since May 2024. Alongside this change, the company welcomed Abizer Gaslightwala as a new director, drawing on his extensive experience in the pharmaceutical sector. The board also acknowledged the resignation of director Michael Grissinger, who left without any disputes regarding the company’s operations.

Akari Therapeutics Appoints Torsten Hombeck as CFO

Akari Therapeutics announced the appointment of Torsten Hombeck as the new Chief Financial Officer, effective December 16, 2024. Dr. Hombeck brings extensive experience in financial leadership within the healthcare and biopharmaceutical sectors, having served in similar roles at various companies including Aspira Women’s Health and Promethera Biosciences, which enhances Akari’s strategic positioning in the financial domain.

Akari Therapeutics Announces Leadership Restructuring

Akari Therapeutics announced a leadership change, with the termination of Wendy DiCicco’s role as Interim Chief Financial Officer. Samir Patel, the Interim CEO, has been appointed as Interim Principal Financial Officer and Principal Accounting Officer while the search for a permanent CFO is underway.

Akari Therapeutics Advances Post-Merger with Strategic Moves

Akari Therapeutics has completed its merger with Peak Bio, enhancing its focus on developing therapies for autoimmune and inflammatory diseases. This strategic move also includes a $3.2 million private placement financing and a $50 million equity line of credit, potentially strengthening its financial standing post-merger. The combined entity aims to advance its innovative pipeline, particularly in Antibody Drug Conjugates and Geographic Atrophy therapies, ensuring the continuation of milestone achievements. These developments are crucial for Akari’s ongoing efforts to meet Nasdaq listing requirements.

Akari Therapeutics Merges with Peak Bio for Growth

Akari Therapeutics recently secured shareholder approval for its merger with Peak Bio, a significant milestone in the companies’ strategic alignment. The merger, characterized by a 50-50 equity exchange between the entities, aims to fortify their positions in the biotechnology sector, focusing on innovative therapies like Antibody Drug Conjugates (ADC) and Geographic Atrophy (GA) treatments. This merger is anticipated to resolve Akari’s Nasdaq listing concerns, paving the way for enhanced market presence and development in autoimmune and inflammatory disease therapies.